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A bs tr ac t
Background
Epidemiologic data suggest that infection with herpes simplex virus type 2 (HSV-2) 
is associated with increased genital shedding of human immunodeficiency virus 
type 1 (HIV-1) RNA and HIV-1 transmissibility.
Methods
We conducted a randomized, double-blind, placebo-controlled trial of HSV suppres-
sive therapy with valacyclovir (at a dose of 500 mg twice daily) in Burkina Faso among 
women who were seropositive for HIV-1 and HSV-2; all were ineligible for highly 
active antiretroviral therapy. The patients were followed for 24 weeks (12 weeks 
before and 12 weeks after randomization). Regression models were used to assess the 
effect of valacyclovir on the presence and quantity of genital and plasma HIV-1 RNA 
and genital HSV-2 DNA during treatment, adjusting for baseline values, and to 
evaluate the effect over time.
Results
A total of 140 women were randomly assigned to treatment groups; 136 were in-
cluded in the analyses. At enrollment, the median CD4 cell count was 446 cells per 
cubic millimeter, and the mean plasma viral load was 4.44 log10 copies per millili-
ter. With the use of summary-measures analysis, valacyclovir therapy was found to 
be associated with a significant decrease in the frequency of genital HIV-1 RNA 
(odds ratio, 0.41; 95% confidence interval [CI], 0.21 to 0.80) and in the mean quan-
tity of the virus (log10 copies per milliliter, −0.29; 95% CI, −0.44 to −0.15). How-
ever, there was no significant decrease in detection of HIV (risk ratio, 0.93; 95% CI, 
0.81 to 1.07). HSV suppressive therapy also reduced the mean plasma HIV-1 RNA 
level by 0.53 log10 copy per milliliter (95% CI, −0.72 to −0.35). Repeated-measures 
analysis showed that these effects became significantly stronger during the 3 months 
of follow-up.
Conclusions
HSV suppressive therapy significantly reduces genital and plasma HIV-1 RNA levels 
in dually infected women. This finding may have important implications for HIV 
control. (ClinicalTrials.gov number, NCT00158509.)
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Epidemiologic and biologic data sup-port a strong association between herpes simplex virus type 2 (HSV-2) and infection 
with human immunodeficiency virus type 1 
(HIV-1).1-5 A recent meta-analysis of prospective 
observational studies showed that patients who 
were seropositive for HSV-2 had three times the 
risk of acquiring HIV-1, as compared with those 
who were seronegative for the virus.6 In addition, 
three of four studies showed that HSV-2 infection 
may increase the quantity of genital HIV-1 RNA.7-10 
This association probably arises from both symp-
tomatic11 and asymptomatic genital shedding of 
HSV-2 DNA, although the evidence for the latter 
is weaker.12 The biologic plausibility of HSV-2 as 
a facilitator for genital HIV-1 RNA is supported by 
various mechanisms, including local influx of 
activated CD4+ lymphocytes in HSV-infected le-
sions13 and transactivation of the HIV-1 tat protein 
and long terminal repeat genes by HSV-2 pro-
teins.14-16 This could result in greater HIV-1 repli-
cation at the genital mucosal level and possibly 
also at the systemic level. In support of the latter 
hypothesis, symptomatic HSV-2 reactivation has 
been associated with transient increases in plasma 
HIV-1 RNA levels17 and acyclovir treatment with 
reduced plasma HIV-1 RNA levels.18
To establish a relationship between HSV-2 and 
HIV-1 replication, randomized, controlled trials 
of HSV-2 control strategies are required.3,19 Our 
trial, sponsored by the Agence Nationale de Re-
cherches sur le SIDA under grant number 1285 
(ANRS 1285), was a randomized, controlled 
study to determine whether HSV suppressive ther-
apy reduces HIV-1 replication among dually infect-
ed women in Bobo-Dioulasso, Burkina Faso.
Patien t s a nd Me thods
Study Design
We conducted a double-blind, placebo-controlled 
trial of 500 mg of valacyclovir twice daily for 
3 months among women who were dually infected 
with HIV-1 and HSV-2. None of the women in the 
study were eligible for highly active antiretroviral 
therapy (HAART), according to recommendations 
of the World Health Organization (WHO) for de-
veloping countries.20 The study protocol was ap-
proved by the institutional review board at Centre 
Muraz and the ethics committees at the Burkina 
Faso Ministry of Health and the London School 
of Hygiene and Tropical Medicine. All patients 
provided written informed consent.
Patients
Study patients were recruited from the Yerelon 
cohort of high-risk women described elsewhere,21 
from local organizations for people living with 
HIV/AIDS (PLWHA), and from the University Hos-
pital in Bobo-Dioulasso. Women who were at least 
16 years of age, had serum antibodies to both 
HSV-2 and HIV-1, and were not eligible for 
HAART could enroll in the study. Exclusion crite-
ria were significant renal impairment (defined as 
a serum creatinine level of more than twice the 
normal value) or hypersensitivity to acyclovir; 
breast-feeding, pregnancy, or a desire to become 
pregnant in the next 6 months; or a medical indi-
cation for HSV suppressive therapy (≥6 clinical 
episodes per year).
Trial Procedures
At a screening visit, women were informed of the 
aims and procedures of the trial and were assessed 
for eligibility. A blood sample was collected from 
consenting women for serologic tests, CD4 lym-
phocyte count, and assessment of renal function. 
Eligible women underwent an informed-consent 
process and a 1-week reflection period and then 
entered the baseline phase, which consisted of 
six visits every other week. At the scheduled sixth 
visit, eligibility criteria were reassessed, and after 
collection of appropriate samples, eligible patients 
were randomly assigned to two groups by means 
of a 1:1 allocation scheme with block randomiza-
tion of 10 patients and following a random-allo-
cation list independently provided by the study 
drug manufacturer. This list was kept by the stat-
istician for the data and safety monitoring com-
mittee. Prelabeled, sequentially numbered treat-
ment packs were used; investigators and patients 
were unaware of study-group assignments. The 
treatment lasted 12 weeks, with six visits every 
other week starting 2 weeks after randomization.
At each of the 12 visits, a physician performed 
a gynecologic examination and collected samples. 
Menstruating women were deferred for genital 
sampling until 2 days after bleeding had ceased. 
During the treatment phase, the physician collect-
ed empty drug packs for pill counts, recorded and 
graded adverse events, counseled patients on com-
pliance and safer-sex measures, and provided 
condoms.
Women who became pregnant discontinued 
the study drug but were invited to continue regu-
lar follow-up procedures. Women with genital 
ulcers were initially treated with antibiotics ac-
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cording to national guidelines for the treatment 
of sexually transmitted infections. After 7 days, 
nonhealing ulcers were treated with open-label 
acyclovir (at a dose of 200 mg five times daily for 
5 days). The assigned study drug was not discon-
tinued. In addition, both episodic and suppres-
sive therapy with acyclovir remained available to 
patients after the end of the trial.
Sample Collection
At each visit, swabs were collected for diagnosis 
of vaginal infections, and cervicovaginal lavage 
enriched by cervical swabbing was performed for 
the detection and quantitation of genital HIV-1 
RNA and HSV-2 DNA, as previously described.22 
At enrollment, additional cervical swabs were col-
lected for the diagnosis of Neisseria gonorrhoeae 
and Chlamydia trachomatis (Amplicor NG/CT, Roche 
Diagnostics).
Blood samples were drawn on alternate visits 
for the quantitation of plasma HIV-1. Urine sam-
ples were collected before randomization and once 
a month during the treatment phase for preg-
nancy testing (Vikia hCG-S, BioMérieux).
Laboratory Analyses
Serologic Assays and CD4+ Analysis
Depending on the source of recruitment, HIV-1 
seropositivity was determined with the use of 
either an enzyme-linked immunosorbent assay 
(ELISA) or a rapid-testing strategy with Determine 
(Abbott), followed by Genie II (BioRad), as recom-
mended by the WHO.23 The presence of HSV-2 
antibodies was detected by means of a specific 
IgG2 ELISA (Kalon Biologicals) with high sensi-
tivity and specificity in African serum samples.24 
Serologic diagnosis of syphilis was based on pos-
itive results on the rapid plasma reagin test (RPR, 
BioMérieux) and Treponema pallidum hemagglutina-
tion assay (TPHA, Newmarket Laboratories). The 
CD4+ lymphocyte count was performed with a 
standard fluorocytometry technique (FACScan, 
Becton Dickinson).
HIV-1 RNA and HSV-2 DNA
HIV-1 RNA and HSV-2 DNA were quantitated by 
real-time polymerase-chain-reaction assay with 
the use of the ABI 7000 system and manual nu-
cleic acid extraction (Qiagen RNA and DNA kits), 
as described previously.22,25,26 Testing of genital 
HIV-1 RNA was performed in duplicate, and the 
mean value of the two measures was used in the 
analyses. The Centre Muraz laboratory partici-
pated in an external quality-control program for 
HIV-1 RNA quantitation organized by ANRS, and 
the University of Montpellier Virology Laboratory 
used a commercial panel (HSV 1/2 Clear QC panel, 
Argene) as an internal quality control for HSV-2 
DNA quantitation.
Vaginal Infections
Trichomonas vaginalis and Candida albicans were 
identified by culture on the InPouch TV (Biomed 
Diagnostics) and Sabouraud’s milieu, respectively. 
Bacterial vaginosis was diagnosed from Gram-
stained vaginal smears with the use of the Nugent 
standardized scoring system, based on a weight-
ed combination of different morphotypes: lacto-
bacilli, Gardnerella vaginalis or bacteroides, and 
curved gram-variable rods.27
Study Outcomes
The primary study outcomes were the presence, 
frequency, and quantity of genital HIV-1 RNA dur-
ing the treatment phase. Secondary outcomes in-
cluded the presence and quantity of plasma HIV-1 
RNA, as well as the detection of genital HSV-2 
DNA and genital ulcers during the treatment 
phase.
Statistical Analysis
On the basis of data from a pilot study22 and a 
previous African study,7 we estimated that 150 
women were required to detect a reduction of 
0.4 log10 copy per milliliter of genital HIV-1 RNA 
between the two study groups, with an estimated 
variance of 0.5 and a power of 90%, with a 5% 
type I error. Our calculations allowed for a 15% 
loss to follow-up.
Analyses were conducted with Stata statistical 
software, version 9.0 (StataCorp) with the use of 
a modified intention-to-treat approach, in which 
the data for pregnant women were censored at the 
time of the first positive urine test. An a priori 
decision was made to adjust for the pre-random-
ization, baseline-phase genital HIV-1 RNA and 
HSV-2 DNA levels to allow for the variability of 
viral shedding for each of these outcomes respec-
tively.28 A value equal to half the threshold was 
allocated to values below the threshold, including 
undetectable samples, and all viral loads were 
log10-transformed before analysis.
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Primary analyses evaluated the effect per 
woman, using summary measures to combine the 
measurements for each woman into a single 
value. The effect on the presence of HIV-1 RNA or 
HSV-2 DNA at any time during the treatment 
phase (detection) was estimated as a risk ratio, 
using Poisson regression with robust standard 
errors,29 adjusted for the presence of the outcome 
measure during the baseline phase. The frequen-
cy of genital HIV-1 RNA and HSV-2 DNA (the 
proportion of visits during which the virus was 
detected, per woman) was estimated by a propor-
tional-odds–ordered logistic-regression model ad-
justed for baseline frequency. Linear regression 
was used to compare the mean levels of genital 
or plasma HIV-1 RNA (in log10 copies per milli-
liter) between the study groups, adjusted for mean 
baseline values. Unadjusted measures of effect are 
also shown, and all reported P values are two-
sided.
Further analyses were carried out on a per-
visit basis with the use of repeated-measures 
analysis. Risk ratios were estimated by means of 
Poisson regression models fitted with generalized 
estimating equations with an exchangeable cor-
relation matrix. The effect of the intervention on 
the presence of genital HIV-1 RNA and HSV-2 
DNA was assessed by including an interaction 
term for the baseline or treatment phase and the 
study group. The trend of the treatment effect 
with time was evaluated by including an interac-
tion term for study group and time. The effect of 
valacyclovir on the quantity of genital HIV-1 RNA 
was assessed with the use of random-effects 
linear regression among visits with detectable 
HIV-1 RNA only, owing to the high proportion 
of patients with no detectable shedding of the 
virus. The effect on the quantity of plasma HIV-1 
RNA was assessed during all visits.
R esult s
Of 195 women who underwent screening, 150 
were eligible to participate in the study; 148 were 
enrolled in the baseline phase of the study be-
tween August 2004 and January 2005. Of these, 
140 women were randomly assigned to study 
groups, and 136 (68 in each group) were included 
in the analyses (Fig. 1). The mean age of partici-
pants was 32 years (range, 16 to 50), the median 
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Figure 1. Enrollment and Outcomes.
During follow-up, data were censored for five women in the valacyclovir 
group and six in the placebo group for various reasons, including pregnan-
cy. However, their data were included in the intention-to-treat analysis. Fur-
ther serologic analysis revealed that two women in each study group tested 
positive for infection with HIV-2, which was an enrollment error, and these 
women were excluded from all analyses. HAART denotes highly active anti-
retroviral therapy.
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CD4 cell count was 446 cells per cubic millimeter 
(interquartile range, 334 to 628), and the mean 
plasma HIV-1 RNA level was 4.44 log10 copies per 
milliliter (95% confidence interval [CI], 4.25 to 
4.62) at enrollment. There were no major differ-
ences at enrollment between the study groups 
with regard to predefined demographic, behavior-
al, and clinical characteristics (Table 1). However, 
the mean quantity of plasma HIV-1 RNA and the 
proportion of visits with detectable genital HIV-1 
were higher in the placebo group during the entire 
baseline phase (Table 2).
During the treatment phase, data from 11 
women were censored (5 in the valacyclovir group 
and 6 in the placebo group) owing to pregnancy, 
dropout, or travel (Fig. 1). Overall, of 408 possible 
visits, 376 (92.2%) were completed in the valacy-
clovir group and 374 (91.7%) in the placebo group. 
On the basis of the pill count, the average treat-
ment compliance was 97.2% (95% CI, 94.0 to 
100.0) in the valacyclovir group and 96.7% (95% 
CI, 94.6 to 98.9) in the placebo group. No serious 
adverse events or cases of hepatic or renal im-
pairment associated with valacyclovir were report-
ed, and the frequency of mild-to-moderate side 
effects was similar in the two groups (Table 3).
As compared with women who never shed 
HSV-2 during the baseline phase, women with 
detectable HSV-2 DNA at least once during the 
baseline phase were found to have significantly 
higher mean viral loads (in log10 copies per milli-
liter) of genital HIV-1 RNA (3.04 for those with 
some HSV-2 shedding vs. 2.81 for those without 
shedding, P = 0.05) and plasma HIV-1 RNA levels 
(4.75 for those with some HSV-2 shedding vs. 4.24 
for those without shedding, P = 0.001) during the 
baseline phase.
Effect of Treatment
Genital HIV-1 RNA
Valacyclovir had a nonsignificant effect on the 
proportion of women who had detectable HIV-1 
RNA at least once (risk ratio, 0.93; 95% CI, 0.81 
to 1.07). However, treatment was associated with 
a significant reduction in the frequency of geni-
tal HIV-1 RNA (odds ratio, 0.41; 95% CI, 0.21 to 
0.80) (Table 2 and Fig. 2), adjusted for correspond-
ing values in the baseline phase. In addition, the 
mean quantity of genital HIV-1 RNA was signifi-
cantly lower in the valacyclovir group (mean re-
duction adjusted for baseline-phase values, −0.29 
log10 copy per milliliter; 95% CI, −0.44 to −0.15; 
P<0.001).
Table 1. Characteristics of the Patients at Baseline.*
Characteristic
Placebo
(N = 68)
Valacy­clovir
(N = 68)
Age — no. (%)†
16–24 yr 10 (14.9) 12 (18.5)
25–34 yr 33 (49.3) 32 (49.2)
≥35 yr 24 (35.8) 21 (32.3)
Source of recruitment — no. (%)
Sex worker 48 (70.6) 39 (57.4)
PLWHA organizations 13 (19.1) 25 (36.8)
Hospital outpatient 7 (10.3) 4 (5.9)
Age when first had sex — yr
Median 16 16
Interquartile range 15–17 15–18
No. of sex acts in previous week — no. (%)
None 22 (32.4) 26 (38.2)
1–5 37 (54.4) 31 (45.6)
≥6 9 (13.2) 11 (16.2)
Contraceptive use — no. (%)
None 26 (38.2) 31 (45.6)
Hormonal contraception 9 (13.2) 10 (14.7)
Intrauterine device 0 1 (1.5)
Condom 33 (48.5) 26 (38.2)
Frequency of vaginal douching — no. (%)
Never 7 (10.3) 9 (13.2)
Once a day or less 33 (48.5) 35 (51.5)
More than once a day 28 (41.2) 24 (35.3)
Condom use with last regular partner — no. (%)
No. of patients 46 38
No 2 (4.3) 2 (5.3)
Yes 44 (95.7) 36 (94.7)
Stage of HIV infection — no. (%)‡
I 33 (48.5) 35 (51.5)
II or III 35 (51.5) 32 (47.1)
Unknown 0 1 (1.5)
CD4 lymphocyte count per mm3
Median 435 451
Interquartile range 319–637 339–683
Plasma HIV-1 RNA — log10 copies per ml
Mean 4.66 4.29
95% CI  4.48–4.84 4.02–4.54
Serologic syphilis (RPR+/TPHA+) — no. (%) 0 1 (1.5)
Neisseria gonorrhoeae — no. (%) 0 0
Chlamydia trachomatis — no. (%)§ 2 (3.2) 1 (1.6)
Trichomonas vaginalis — no. (%) 4 (5.9) 1 (1.5)
Candida albicans — no. (%) 7 (10.3) 4 (5.9)
Bacterial vaginosis — no. (%) 23 (33.8) 24 (35.3)
* PLWHA denotes people living with HIV/AIDS, RPR rapid plasma reagin, and 
TPHA Treponema pallidum hemagglutination assay. Percentages may not total 
100 because of rounding.
† Data were missing for three patients in the valacyclovir group and one patient 
in the placebo group.
‡ Infections were staged according to the criteria of the World Health Organization.
§  Data were missing for seven women in the valacyclovir group and six women 
in the placebo group.
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Table 2. Analy­sis of Genital and Plasma HIV-1 RNA, Genital HSV-2 DNA, and Genital Ulcerations According to Study­ Phase and Group.*
Unadjusted 
Measure 
of Effect 
(95%CI)
Adjusted 
Measure 
of Effect† 
(95%CI)
P Value 
for Adjusted 
Analy­sisVariable Baseline Phase Treatment Phase
Placebo
(N = 68)
Valacyclovir
(N = 68)
Placebo
(N = 68)
Valacyclovir
(N = 68)
Summary­-measures analy­sis
Genital HIV-1 RNA detected
At least once — no. (%) 61 (89.7) 54 (79.4) 59 (86.8) 51 (75.0) RR = 0.86
(0.73 to 1.02)
RR = 0.93
(0.81 to 1.07)
0.30
At no visit — no. (%) 7 (10.3) 14 (20.6) 9 (13.2) 17 (25.0) OR = 0.34‡
(0.18 to 0.65)
OR = 0.41‡
(0.21 to 0.80)
0.009
At <50% of visits — no. (%) 11 (16.2) 17 (25.0) 10 (14.7) 23 (33.8)
At 50–99% of visits — no. (%) 40 (58.8) 27 (39.7) 31 (45.6) 19 (27.9)
At all visits — no. (%) 10 (14.7) 10 (14.7) 18 (26.5) 9 (13.2)
Mean quantity — log10 copies/ml 2.97 2.87 3.02 2.65 −0.37
(−0.59 to −0.14)
−0.29  
(−0.44 to −0.15)
<0.001
95% CI 2.83 to 3.11 2.68 to 3.05 2.86 to 3.19 2.50 to 2.81
Plasma HIV-1 RNA detected
At least once — no. (%)§ 68 (100.0) 63 (92.6) 67 (100.0) 61 (92.4) RR = 0.92
(0.86 to 0.99)
RR = 0.98 
(0.95 to 1.02)
0.32
Mean quantity — log10 copies/ml 4.66 4.29 4.81 3.94  −0.87
(−1.19 to −0.55)
 −0.53
(−0.72 to −0.35)
<0.001
95% CI 4.48 to 4.84 4.02 to 4.54 4.61 to 5.01 3.67 to 4.20
Genital HSV-2 DNA detected
At least once — no. (%) 31 (45.6) 30 (44.1) 37 (54.4) 13 (19.1) RR = 0.35
(0.20 to 0.60)
RR = 0.35
(0.21 to 0.60)
<0.001
At no visit — no. (%) 37 (54.4) 38 (55.9) 31 (45.6) 55 (80.9) OR = 0.18‡
(0.08 to 0.39)
OR = 0.17‡
(0.07 to 0.38)
<0.001
At <50% of visits — no. (%) 26 (38.2) 29 (42.6) 28 (41.2) 13 (19.1)
At 50–99% of visits — no. (%) 5 (7.4) 1 (1.5) 8 (11.8) 0
At all visits — no. (%) 0 0 1 (1.5) 0
At least one episode of vesicle or gen-
ital ulceration — no. (%)
19 (27.9) 20 (29.4) 19 (27.9) 3 (4.4) RR = 0.16 
(0.05 to 0.51)
RR = 0.16  
(0.05 to 0.49)
0.002
Repeated-measures analy­sis 
Genital HIV-1 RNA
Virus detected — no./total no. of 
visits (%)
235/391
(60.1)
190/393 
(48.3)
232/364 
(63.7)
142/366 
(38.8)
RR = 0.62
(0.49 to 0.80)
RR = 0.77
(0.64 to 0.93)
0.006
Mean quantity — log10 copies/ml 3.54 3.70 3.60 3.54 −0.11
(−0.32 to −0.09)
−0.28
(−0.46 to −0.09)
0.003
95% CI 3.46 to 3.63 3.59 to 3.81 3.51 to 3.70 3.40 to 3.67
Plasma HIV-1 RNA
Mean quantity — log10 copies/ml 4.65 4.33 4.76 3.93 −0.86
(−1.18 to −0.54)
−0.45
(−0.62 to −0.29)
<0.001
95% CI 4.53 to 4.77 4.17 to 4.49 4.64 to 4.89 3.76 to 4.10
Genital HSV-2 DNA detected — 
no./total no. of visits (%)
50/393
(12.7)
38/394
(9.6)
66/368 
(17.9)
15/368
(4.1)
RR = 0.22
(0.12 to 0.40)
RR = 0.29
(0.14 to 0.58)
0.001
* Mean quantities of virus were compared with the use of a regression coefficient. CI denotes confidence interval, RR risk ratio, and OR odds 
 ratio. Percentages may not total 100 because of rounding.
† Values are adjusted for the outcome measure in the baseline phase.
‡ The odds ratio is for the last four categories in the variable. 
§ Data regarding plasma HIV-1 RNA were missing for two women in the valacyclovir group and one woman in the placebo group during the 
treatment phase.
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The repeated-measures analysis confirmed 
these results (Table 2) and found that the num-
ber of visits in which women had detectable geni-
tal HIV-1 RNA was significantly lower in the 
valacyclovir group (risk ratio, 0.77; 95% CI, 0.64 
to 0.93; P = 0.006). Further analyses showed an 
increase in treatment effect over time for both the 
presence of detectable genital HIV-1 RNA (risk 
ratio for every 2-week period during treatment 
phase, 0.93; 95% CI, 0.88 to 0.97; P = 0.001) and 
the quantity of genital HIV-1 RNA (average re-
duction in mean quantity every 2 weeks during 
the treatment phase, 0.08 log10 copy per millili-
ter; 95% CI, 0.04 to 0.11; P<0.001) (Fig. 2).
Plasma HIV-1 RNA
The mean quantity of plasma HIV-1 RNA among 
women in the valacyclovir group was significantly 
lower than in the placebo group (−0.53 log10 copy 
per milliliter; 95% CI, −0.72 to −0.35, adjusted for 
mean baseline-phase value; P<0.001). A similar re-
sult was found with the use of a repeated-measures 
analysis (Table 2). In addition, the treatment ef-
fect on plasma HIV-1 RNA increased with time 
(P<0.001), with an average reduction of 0.09 log10 
copy per milliliter every 2 weeks (95% CI, 0.05 to 
0.12; P<0.001).
Genital HSV-2 DNA
As expected, valacyclovir was highly effective in 
lowering the detection and frequency of genital 
HSV-2 DNA. Significantly fewer women in the 
valacyclovir group shed HSV-2 at all during the 
treatment phase: 19.1% in the valacyclovir group 
vs. 54.4% in the placebo group (risk ratio, 0.35; 
95% CI, 0.21 to 0.60; P<0.001). In addition, the 
frequency of detection of genital HSV-2 DNA was 
strongly reduced in the valacyclovir group (odds 
ratio, 0.17; 95% CI, 0.07 to 0.38; P<0.001) (Table 2). 
Results were confirmed by repeated-measures 
analysis (Table 2). In a similar way, the propor-
tion of women with at least one genital ulcer de-
clined from baseline in the valacyclovir group, 
from 29.4% in the baseline phase to 4.4% in the 
treatment phase, as compared with no change in 
the placebo group (risk ratio, 0.16; 95% CI, 0.05 to 
0.49; P = 0.002).
Discussion
Daily treatment with valacyclovir for 3 months 
significantly diminished the shedding of HIV-1 
RNA, reduced plasma HIV-1 RNA levels, and re-
duced genital HIV-1 RNA levels when shedding 
was present in women dually infected with HIV-1 
and HSV-2. This effect steadily increased over 
time, which suggested that a longer duration of 
treatment might have led to an even greater re-
duction in HIV-1 RNA levels. These findings should 
be verified through clinical trials of longer dura-
tion. The effect of acyclovir on plasma HIV-1 RNA 
has been observed previously among 12 patients 
who were seropositive for HSV-2 and HIV-1.18 
Acyclovir is unlikely to have a direct pharmaco-
logic effect on HIV-1,30 and hence the most plau-
sible explanation is that HSV suppressive therapy 
prevents clinical and subclinical reactivations re-
sponsible for an increased HIV-1 viral load. In-
deed, HSV reactivation generates an influx of ac-
tivated CD4+ T lymphocytes31 and significantly 
up-regulates HIV-1 replication.14-16,32 Transient 
HIV-1 systemic reactivation has been demonstrat-
ed during clinical HSV-2 episodes.17,18 In addition, 
subclinical HSV-2 episodes have been associated 
with mucosal disruption and lymphocytic infil-
tration similar to that found in clinical genital 
herpetic lesions,33 which suggests that asymp-
tomatic HSV-2 shedding may act similarly and 
maintain HIV-1 replication at a high level. Data 
from our baseline phase support this hypothesis, 
Table 3. Adverse Events.*
Event
Placebo
(N = 68)
Valacy­clovir
(N = 68) P Value
no. (%)
Nausea 7 (10.3) 11 (16.2) 0.31
Vomiting 6 (8.8) 4 (5.9) 0.51
Diarrhea 7 (10.3) 3 (4.4) 0.19
Dysphagia 3 (4.4) 1 (1.5) 0.31
Constipation 10 (14.7) 5 (7.4) 0.17
Dyspnea 3 (4.4) 2 (2.9) 0.65
Anxiety 2 (2.9) 3 (4.4) 0.65
Headache 27 (39.7) 20 (29.4) 0.21
Hypersensitivity reactions 14 (20.6) 10 (14.7) 0.37
Renal colic 1 (1.5) 0 0.32
Paresthesia 11 (16.2) 4 (5.9) 0.06
Myalgia 2 (2.9) 4 (5.9) 0.40
Fatigue 17 (25.0) 10 (14.7) 0.13
Arthralgia 3 (4.4) 6 (8.8) 0.30
* All adverse events were mild to moderate (category 1 or 2 on a 4-point scale).
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with higher quantities of genital and plasma 
HIV-1 RNA among women shedding HSV-2.
Plasma HIV-1 RNA is the strongest predictor 
of genital HIV-1 RNA,34 although some compart-
mentalization of HIV-1 shedding may exist at the 
genital level.34-36 Thus, the effect of HSV suppres-
sive therapy on HIV-1 shedding may simply be 
a consequence of a reduced systemic viral load. 
A complementary explanation would be that direct 
viral interaction occurs at the genital level. A trial 
of similar design conducted among women whose 
disease characteristics qualified them for HAART 
showed that valacyclovir could have a further 
effect on the residual shedding of HIV-1 despite 
good systemic control, which supports an effect 
of HSV-2 on independent mucosal HIV-1 replica-
tion.37
As expected, suppressive therapy with 500 mg 
of valacyclovir twice daily among women with 
HIV-1 infection proved very effective in reducing 
genital ulcerations and genital HSV-2 DNA. The 
effect on clinical episodes was similar to that 
reported in previous suppressive-treatment trials 
among coinfected women.38,39
Our study had several strengths, including a 
high level of compliance with study procedures 
and study drugs. Moreover, repeated-measures 
analysis of viral load allowed for adjustment for 
within-person variability of HSV-2 and HIV-1 
shedding, as seen during the baseline phase.
Although our trial had no HIV clinical out-
comes, its results may be relevant to HIV-1 pre-
vention and management. It is estimated that a 
large proportion of persons who are seropositive 
for HIV-1 are also HSV-2 seropositive.7,40 The 
strong and significant reduction in plasma and 
genital HIV-1 RNA levels associated with valacy-
clovir treatment suggests that sustained forms 
of HSV-2 control (either antiviral therapy or effec-
tive vaccination) may reduce HIV-1 transmission, 
assuming that a reduction in genital and plasma 
HIV-1 RNA levels is a proxy for decreased trans-
missibility.19,41 This finding could be especially 
relevant among populations likely to play an im-
portant role in the dynamics of HIV transmission 
and among couples with discordant HIV status.19 
At the individual level, the reduction in plasma 
HIV-1 RNA levels (with the likely reduction in 
CD4+ activation, which is responsible for T-lym-
phocyte depletion42) may lead to immunologic 
benefit over a longer duration of valacyclovir 
treatment, thereby slowing the course of HIV-1 
disease. In addition to individual benefit regard-
ing clinical recurrence, HSV suppressive therapy 
could also have an effect on HSV-2 transmis-
sion.43
The link between HSV-2 and HIV-1 should 
stimulate the development and evaluation of 
HSV-2 control methods. Several ongoing random-
ized, controlled trials will provide further evi-
dence of the effect of HSV suppressive therapy 
on HIV-1 transmission and acquisition.19 Other 
trials are planned to evaluate the individual bene-
fits, using immunologic and clinical outcomes. In 
particular, research to develop an HSV vaccine 
should rank high on the international research 
agenda for the prevention of HIV and HSV-2. Such 
a vaccine would represent a long-lasting form of 
HSV-2 control and possibly an important tool in 
HIV prevention.
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